Literature DB >> 28521471

Preoperative peripheral blood neutrophil count predicts long-term outcomes following hepatic resection for colorectal liver metastases.

Koichiro Haruki1, Hiroaki Shiba1, Yuki Fujiwara1, Kenei Furukawa1, Tomonori Iida1, Masahisa Ohkuma1, Masaichi Ogawa1, Yuichi Ishida1, Takeyuki Misawa1, Katsuhiko Yanaga1.   

Abstract

Preoperative systemic inflammatory response is associated with a poor long-term prognosis following resection surgery for malignant tumors. Several markers of systemic inflammation have been reported to be associated with the outcome; however, they have not currently been fully investigated. Therefore, the association between preoperative peripheral blood neutrophil count and oncological outcome following hepatic resection for colorectal liver metastasis (CRLM) was retrospectively investigated. The present study comprised 89 patients who had undergone hepatic resection for CRLM between January 2000 and March 2010. The association between preoperative peripheral blood neutrophil count and disease-free survival, in addition to overall survival, was investigated. In multivariate analysis, the presence of neoadjuvant chemotherapy (P=0.015), bilobar distribution (P=0.015) and neutrophil count ≥3,500/µl (P=0.025) were independent and significant predictors of poor disease-free survival, while significant predictors of poor overall survival consisted of >4 lymph node metastases (P=0.001), neo-adjuvant chemotherapy (P=0.003), bilobar distribution (P=0.039) and neutrophil count ≥3,500/µl (P=0.040). Additionally, tumor diameter (P=0.021) and monocyte count (P<0.0001) were observed to be significantly greater in the elevated neutrophil count group. In conclusion, preoperative peripheral blood neutrophil count may be an independent and significant indicator of poor long-term outcomes in patients with CRLM following hepatic resection.

Entities:  

Keywords:  colorectal liver metastases; hepatic resection; neutrophil; prognosis; systemic inflammatory response

Year:  2017        PMID: 28521471      PMCID: PMC5431379          DOI: 10.3892/ol.2017.5873

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  33 in total

1.  Perioperative change in white blood cell count predicts outcome of hepatic resection for hepatocellular carcinoma.

Authors:  Yuki Fujiwara; Hiroaki Shiba; Kenei Furukawa; Tomonori Iida; Taro Sakamoto; Takeshi Gocho; Shigeki Wakiyama; Shoichi Hirohara; Yuichi Ishida; Takeyuki Misawa; Toya Ohashi; Katsuhiko Yanaga
Journal:  J Hepatobiliary Pancreat Sci       Date:  2010-05-07       Impact factor: 7.027

Review 2.  Immunity, inflammation, and cancer.

Authors:  Sergei I Grivennikov; Florian R Greten; Michael Karin
Journal:  Cell       Date:  2010-03-19       Impact factor: 41.582

3.  Neutrophil to lymphocyte ratio predicts pattern of recurrence in patients undergoing liver resection for colorectal liver metastasis and thus the overall survival.

Authors:  Alexandros Giakoustidis; Kyriakos Neofytou; Aamir Z Khan; Satvinder Mudan
Journal:  J Surg Oncol       Date:  2014-12-29       Impact factor: 3.454

4.  Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.

Authors:  Lieke H J Simkens; Harm van Tinteren; Anne May; Albert J ten Tije; Geert-Jan M Creemers; Olaf J L Loosveld; Felix E de Jongh; Frans L G Erdkamp; Zoran Erjavec; Adelheid M E van der Torren; Jolien Tol; Hans J J Braun; Peter Nieboer; Jacobus J M van der Hoeven; Janny G Haasjes; Rob L H Jansen; Jaap Wals; Annemieke Cats; Veerle A Derleyn; Aafke H Honkoop; Linda Mol; Cornelis J A Punt; Miriam Koopman
Journal:  Lancet       Date:  2015-04-07       Impact factor: 79.321

5.  Perioperative change in peripheral blood monocyte count may predict prognosis in patients with colorectal liver metastasis after hepatic resection.

Authors:  Koichiro Haruki; Hiroaki Shiba; Yuki Fujiwara; Kenei Furukawa; Shigeki Wakiyama; Masaichi Ogawa; Yuichi Ishida; Takeyuki Misawa; Katsuhiko Yanaga
Journal:  J Surg Oncol       Date:  2012-01-09       Impact factor: 3.454

6.  Preoperative systemic inflammation and infectious complications after resection of colorectal liver metastases.

Authors:  Christopher P Neal; Christopher D Mann; Giuseppe Garcea; Christopher D Briggs; Ashley R Dennison; David P Berry
Journal:  Arch Surg       Date:  2011-04

7.  Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy.

Authors:  Hiroshi Nakano; Elie Oussoultzoglou; Edoardo Rosso; Selenia Casnedi; Marie-Pierre Chenard-Neu; Patrick Dufour; Philippe Bachellier; Daniel Jaeck
Journal:  Ann Surg       Date:  2008-01       Impact factor: 12.969

8.  Systemic inflammatory response predicts survival following curative resection of colorectal cancer.

Authors:  D C McMillan; K Canna; C S McArdle
Journal:  Br J Surg       Date:  2003-02       Impact factor: 6.939

9.  Preoperative prognostic score for predicting survival after hepatic resection for colorectal liver metastases.

Authors:  Hassan Z Malik; K Rajendra Prasad; Karim J Halazun; Amir Aldoori; Ahmed Al-Mukhtar; Dhanwant Gomez; J Peter A Lodge; Giles J Toogood
Journal:  Ann Surg       Date:  2007-11       Impact factor: 12.969

10.  Postoperative peak serum C-reactive protein predicts outcome of hepatic resection for hepatocellular carcinoma.

Authors:  Hiroaki Shiba; Kenei Furukawa; Yuki Fujiwara; Yasuro Futagawa; Koichiro Haruki; Shigeki Wakiyama; Yuichi Ishida; Takeyuki Misawa; Katsuhiko Yanaga
Journal:  Anticancer Res       Date:  2013-02       Impact factor: 2.480

View more
  1 in total

1.  Elevated peripheral absolute monocyte count related to clinicopathological features and poor prognosis in solid tumors: Systematic review, meta-analysis, and meta-regression.

Authors:  Shu Wen; Nan Chen; Ying Hu; Litao Huang; Jin Peng; Meina Yang; Xiaoyang Shen; Yang Song; Liangzhi Xu
Journal:  Cancer Med       Date:  2021-02-16       Impact factor: 4.452

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.